Meng-Fey Lin-Duffy, DO
Surgical Oncology · S Pasadena, CANPI 1609108836
Payments from drug & device makers
Across 63 payments — averaging $40.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Focal Therapeutics, Inc.$522
- Bioptics, Inc.$509
- Hologic Inc$243
- Bristol Myers Squibb$184
- Tempus AI, Inc$169
- Novartis$167
- plus $772 from 18 others
What the payments were for
- Travel & lodging$63925%
- Food & beverage$1,92775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Focal Therapeutics, Inc. | 2 | $522 |
| Bioptics, Inc. | 2 | $509 |
| Hologic Inc | 2 | $243 |
| Bristol Myers Squibb | 8 | $184 |
| Tempus AI, Inc | 8 | $169 |
| Novartis | 8 | $167 |
| Smith+Nephew | 1 | $131 |
| Mirati Therapeutics, Inc. | 4 | $85 |
| Amgen | 3 | $73 |
| Genentech USA, Inc. | 3 | $66 |
| Beigene USA, Inc. | 2 | $62 |
| Johnson & Johnson | 3 | $52 |
| AstraZeneca | 3 | $43 |
| Hologic Sales And Service, LLC | 1 | $40 |
| Clovis Oncology, Inc. | 3 | $39 |
| Octapharma USA, Inc. | 2 | $35 |
| Incyte Corporation | 1 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Verastem, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,565 in reported general payments places this provider in the 50th percentile of 209 surgical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ibuprofen | 17 | $64 |
| Tramadol Hcl | 21 | $37 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in S Pasadena
- Laura EssermanSan Francisco$60.9M
- Robina SmithFullerton$5.8M
- Afshin BahadorSan Diego$701K
- Thomas Lomisvan Nuys$612K
- Trevan FischerSanta Monica$341K
- Amir FathiFresno$285K
- Mark GirgisLos Angeles$243K
- Alexander ChristSanta Monica$239K
- Sepideh GholamiSacramento$237K
- Yanghee WooDuarte$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.